Market Access Today的动态

Stage 1 Breast Cancer Treatment, Shocking Lack of Outcome Data i was a little shocked when I read the literature that moving treatment with a certain targeted HER2 oncolytic to Stage 1 was done without a comparator arm. OK, mechanism well understood. But what really shocked me was the absence of data for older woman. The closest was an article in NATURE 2024 (link in comments) with tiny numbers for older women within 1A, 1B, or 1C. I am quite serious about the need to understand the gains compared to side effects especially with taxol in the mix along with Her2 targeted therapies for someone who is 60, 65 or 70+ And the following new AJMC is a reason why knowing the risk along with the PFS or survival gains in older women is important: “cardiovascular disease (CVD) remains the leading cause of mortality among women and often intersects with breast cancer. This connection is most prominent in those undergoing treatments such as anthracyclines or HER2-targeted cancer therapy, due to their cardiotoxic effects.3?Furthermore, breast cancer survivors with CVD have a 1.24-fold higher risk of dying than those without a history of CVD.4?“ The answer by oncologists in response to complaints by older patients about lack of data “get used to it”, is a disservice, when older woman give up say a tenth of their expected remaining time for treatment in return for? #Her2 #AHA #AARP #BCS #Komen #ACA Marty Makary M.D., M.P.H.

"There were 8297 ovarian cancer decedents. Their mean (SD) age at death was 69.6 (13.1) years, and their mean (SD) oncologic survival was 2.8 (3.9) years. Among 3958 patients with known cancer stage, 3495 (88.3%) presented with stage III or IV disease. One-third of patients (2667 [32.1%]) received late palliative care in the final 3 months of life. Results of multivariable regression analysis indicated that any palliative care initiated earlier than 3 months before death was associated with lower rates of aggressive end-of-life care (odds ratio [OR], 0.47 [95% CI, 0.37-0.60]), death in hospital (OR, 0.54 [95% CI, 0.45-0.65]), and intensive care unit admission (OR, 0.46 [95% CI, 0.27-0.76]). Specialist palliative consultation from 3 months up to 6 monts before death was associated with decreased likelihood of late chemotherapy (OR, 0.46 [95% CI, 0.24-0.88])."

"There were 8297 ovarian cancer decedents. Their mean (SD) age at death was 69.6 (13.1) years, and their mean (SD) oncologic survival was 2.8 (3.9) years. Among 3958 patients with known cancer stage, 3495 (88.3%) presented with stage III or IV disease. One-third of patients (2667 [32.1%]) received late palliative care in the final 3 months of life. Results of multivariable regression analysis indicated that any palliative care initiated earlier than 3 months before death was associated with lower rates of aggressive end-of-life care (odds ratio [OR], 0.47 [95% CI, 0.37-0.60]), death in hospital (OR, 0.54 [95% CI, 0.45-0.65]), and intensive care unit admission (OR, 0.46 [95% CI, 0.27-0.76]). Specialist palliative consultation from 3 months up to 6 monts before death was associated with decreased likelihood of late chemotherapy (OR, 0.46 [95% CI, 0.24-0.88])."

?? New Study Reveals Strong Link Between Disease-Free Survival and Overall Survival in Early-Stage HER2-Negative Breast Cancer Patients! ?? A groundbreaking analysis of Medicare data involving over 28,000 patients has uncovered significant correlations between disease-free survival (DFS) and overall survival (OS) in early-stage HER2-negative breast cancer. ?? Key Findings: - Median DFS for HR+/HER2- patients: 4.5 years - Median DFS for TNBC patients: 3.0 years - Strong positive correlations between all DFS metrics and OS, particularly with distant disease-free survival (DDFS). These insights suggest that DFS can serve as a reliable surrogate endpoint for OS in clinical trials, potentially streamlining the development of new therapeutic strategies. ?? By integrating these metrics into clinical evaluations, healthcare providers can enhance treatment protocols and improve patient outcomes. For a deeper dive into the study's implications for breast cancer management, click on the link! #BreastCancer #CancerSurvival #ClinicalResearch #ClinicalResearches #Healthcare #PatientCare #Publications #MarketAccess #MarketAccessToday

?? Brazil Enhances Breast Cancer Care with New Protocols and Technologies! ???? The Brazilian Ministry of Health has announced groundbreaking advancements in public cancer care, introducing the first Clinical Protocol and Therapeutic Guidelines (PCDT) specifically for breast cancer. This initiative aims to standardize screening, diagnosis, and treatment across the nation, ensuring equitable care for all patients. Key highlights include: - Introduction of Advanced Medications: CDK4/6 inhibitors and trastuzumab deruxtecan to reduce mortality rates. - Minimally Invasive Surgical Techniques: Enhancing recovery times while minimizing infection risks. - Doubling Breast Reconstruction Surgeries: Addressing patient demand for improved post-treatment quality of life. - Integration of 67 New Technologies into SUS, with 16 focused on oncology. With a goal to reduce waiting times for critical services to within 30 days, Brazil is setting a new standard in breast cancer treatment. This proactive approach signifies a robust commitment to improving health outcomes and elevating the quality of care for thousands of women annually. ?? Click on the link to learn more about these transformative changes! #BrazilHealth #BreastCancer #CancerCare #HealthEconomics #HealthcareInnovation #PublicHealth #RegulatoryAgencies #MarketAccess #MarketAccessToday

Advancing Care in Elderly Breast Cancer Patients Breast cancer remains one of the most common cancers in elderly patients, and managing this condition effectively presents unique challenges. With advancing age, comorbidities, decreased organ function, and altered pharmacokinetics impact therapeutic choices. However, while older patients may benefit from treatment, they are often underrepresented in clinical trials, leading to a knowledge gap in evidence-based care for this population (Wildiers et al., 2020). Clinical decisions should be grounded in a balanced consideration of efficacy, quality of life, and safety. Recent studies emphasize the importance of personalized treatments, where assessments like the Comprehensive Geriatric Assessment (CGA) guide therapeutic choices to accommodate physical, cognitive, and functional conditions specific to older patients (Biganzoli et al., 2021). By understanding individual risk factors, physicians can tailor treatments that prioritize safety without compromising efficacy, enabling a holistic approach to care. Immunotherapy and targeted therapies have reshaped cancer treatment, offering new options even for older adults. Yet, these therapies can introduce unique side effects, including immune-related adverse events, requiring vigilant pharmacovigilance strategies. Evidence indicates that adverse reactions may vary in elderly patients due to immunosenescence, necessitating adjusted monitoring approaches (Doyen et al., 2019). To bridge the gaps in care for elderly breast cancer patients, it is essential to support research initiatives dedicated to this population. A call for inclusion and adequate representation of older adults in clinical trials could significantly enhance treatment protocols. As clinicians, let us advocate for comprehensive care pathways that integrate oncology expertise with geriatric considerations to ensure optimal outcomes for our elderly patients. #Oncology #BreastCancer #GeriatricOncology #PrecisionMedicine #ElderlyCare References: - Biganzoli, L., et al. (2021). Personalized treatment of breast cancer in older adults. Journal of Geriatric Oncology, 12(4), 555-562. - Doyen, J., et al. (2019). Safety of immunotherapy in elderly patients with cancer. Cancer Treatment Reviews, 75, 40-47. - Wildiers, H., et al. (2020). Under-representation of older adults in oncology trials. The Lancet Oncology, 21(2), e101-e111.

Happy to share our latest publication in Cancer Survivorship Research & Care: ‘Patient activation of breast cancer patients: results from the longitudinal ADAPT Study.’ In the last couple of decades, breast cancer has transformed into a more chronic illness, which means that patients and families are facing new responsibilities in managing their long-term care. An effective indicator of a patient’s ability to engage in self-management is patient activation, which is defined as the knowledge, skills, and confidence a person has to manage their own health and well-being. We found that psychological distress is significantly associated with lower patient activation levels over time. These insights can help healthcare professionals identify patients who may benefit from tailored interventions to enhance activation and improve the efficiency of long-term care. Many thanks to Sofia Georgopoulou, Rafal Kulakowski, Emma Hainsworth, Emma Lidington, Sophie McGrath, Jillian Noble, Leyla Azarang, Dr Susanne Cruickshank & Olga Husson. The Royal Marsden NHS Foundation Trust

As CEO of Orchid Healthcare Solutions, I am proud to announce our Strategic Partnership with FirstHx. This alliance will bring oncology treatment to all, who are in need of access to quality #cancer outcomes in tangable ways. We look forward to the future of technology advances in oncology and on the leading fore front of change in the design of Oncology outcomes and care delivery. If you would like to learn more about how this Parnership provides impact in Oncology care, please use the link in the announcement below. #Cancer #Canceroutcomes #NursingLeadership #cancercare #partnership OncoDaily CancerX Moonshot

A new publication from colleagues in the oesophago-gastric cancer service at Northern Care Alliance NHS Foundation Trust in World Journal of Surgical Oncology. Their research looked at the impacts that the Covid-19 pandemic had on our regional oesophago-gastric cancer service, with a particular focus on longer-term survival. They found: ?? A significant reduction in OG cancer referrals and a higher rate of advanced disease during the initial phase of the pandemic. ?? Subsequent increased rates of advanced disease for surgical patients. ?? No change in 1 or 2-year overall survival for patients diagnosed with OG cancer. ? Importantly, 'standard of care' treatment (with both curative and paliative intent) was maintained throughout the entire period of public restrictions and lockdowns. These findings underscore the ongoing committment from every member of the wider multi-disciplinary team, who worked to ensure our patients continued to receive the best care possible in the most testing circumstances. https://rdcu.be/d6snw

Younger onset age of breast cancer linked to higher risks of incident MI and HF, highlighting the importance of prioritizing cardiovascular health in younger breast cancer patients. Timely intervention crucial to mitigate subsequent cardiovascular disease risks. Find out more: https://lnkd.in/dAXMf3da